Sugi Predict

Sugi Predict / Compounds / SCHEMBL29412930

SCHEMBL29412930

SCHEMBL29412930

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(N)=O

nearest known ligand 0.73

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ NPY2R P49146 8/20 0.67
▸ NPY4R P50391 8/20 0.67
▸ NPY5R Q15761 8/20 0.67
▸ NPY1R P25929 6/20 0.67
▸ TFPI P10646 6/20 0.66
▸ VIPR1 P32241 2/20 0.65
▸ GLP1R P43220 2/20 0.64
▸ VIPR2 P41587 1/20 0.63
▸ PTH1R Q03431 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29977603 0.91 NPY2R (0.69) NPY2RNPY4RNPY5RNPY1RTFPI
Corticorelin Acetate SCHEMBL29357284 0.89 CRHR1 (0.72) NPY2RNPY4RNPY5RNPY1RGLP1R
SCHEMBL30397368 0.88 NPY2R (0.82) NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL30658322 0.88 NPY2R (0.68) NPY2RNPY4RNPY5RNPY1RTFPI
SCHEMBL31182691 0.87 NPY2R (0.62) NPY2RNPY4RNPY5RNPY1RTFPI
Human Neuropeptide Y SCHEMBL29780330 0.87 NPY2R (0.79) NPY2RNPY4RNPY5RNPY1RTFPI
Aviptadil SCHEMBL29357337 0.86 VIPR1 (0.84) VIPR1GLP1RVIPR2PTH1R
SCHEMBL31182700 0.86 CALCR (0.68) NPY2RNPY4RNPY5RNPY1RGLP1R
SCHEMBL30432080 0.86 NPY2R (0.62) NPY2RNPY4RNPY5RNPY1RGLP1R
SCHEMBL30495728 0.86 CALCR (0.60) NPY2RNPY4RNPY5RNPY1RTFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3532092-B1 IMMUNOGLOBULINS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2026-04-29 — — EP claimed
WO-2025133225-A1 PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) PAM THERAGNOSTICS GMBH (DE) 2025-06-26 — — WO claimed
US-20250084143-A1 ANTIGENIC PEPTIDES DERIVING FROM UROCORTIN 3 AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES UNIVERSITÉ PARIS CITÉ (FR) 2025-03-13 — — US claimed
US-20250026803-A1 IMMUNOGLOBULINS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-01-23 — — US claimed
US-12134636-B2 Immunoglobulins and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-11-05 — — US claimed
US-12098179-B2 Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2024-09-24 — — US claimed
US-20240269319-A1 METHODS FOR ASSEMBLING SCAVENGING PARTICLES NANOTICS, LLC 2024-08-15 — — US claimed
US-20240245762-A1 METHODS AND PLATFORMS FOR PROMOTING ANTIGEN-SPECIFIC TOLERANCE IN THE TREATMENT OF TYPE 1 DIABETES AND GRAFT REJECTION AND COMPOSITIONS RELATING THERETO UNIVERSITY OF MARYLAND, BALTIMORE 2024-07-25 — — US claimed
WO-2024118731-A1 CHIMERIC PSEUDOISLETS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-06-06 — — WO claimed
US-11920160-B2 Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells CEDARS-SINAI MEDICAL CENTER (US) 2024-03-05 — — US claimed
WO-2022155188-A9 METHODS AND PLATFORMS FOR PROMOTING ANTIGEN-SPECIFIC TOLERANCE IN THE TREATMENT OF TYPE 1 DIABETES AND GRAFT REJECTION AND COMPOSITIONS RELATING THERETO UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2023-11-16 — — WO claimed
US-20220265667-A1 ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS MC SCIENCES UG (DE) 2022-08-25 — — US claimed
US-11401315-B2 Immunoglobulins and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2022-08-02 — — US claimed
WO-2022155188-A1 METHODS AND PLATFORMS FOR PROMOTING ANTIGEN-SPECIFIC TOLERANCE IN THE TREATMENT OF TYPE 1 DIABETES AND GRAFT REJECTION AND COMPOSITIONS RELATING THERETO UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2022-07-21 — — WO claimed
EP-3123169-B1 FLATTOP (FLTP) IS A NOVEL BIOMARKER FOR BETA CELL MATURATION HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) 2022-05-04 — — EP claimed
CN-114129737-A Compositions and methods relating to particle removal 纳米提克斯有限责任公司 2022-03-04 — — CN claimed
EP-4746878-A1 METHODS OF TREATING CARDIOMYOPATHY INDUCED BY METABOLIC INFLEXIBILITY Betagenon AB (SE) 2026-05-27 — — EP disclosed
EP-4746879-A1 METHODS FOR REGULATING BLOOD GLUCOSE LEVELS USING A DUAL AMPK ACTIVATOR AND MITOCHONDRIAL UNCOUPLER Betagenon AB (SE) 2026-05-27 — — EP disclosed
CN-114129737-A Compositions and methods relating to particle removal 纳米提克斯有限责任公司 2022-03-04 — — CN disclosed
WO-2022043969-A1 INTERFERENCE PEPTIDES AS INHIBITORS OF INTERACTIONS RELATED TO AMPAR ENDOCYTOSIS SZEDLACSEK STEFAN EUGEN (RO) 2022-03-03 — — WO disclosed
Send feedback